A Phase 4 interventional study of Celecoxib and Diclofenac in Osteoarthritis, Hip, sponsored by Pfizer. Completed at 44 sites in United Kingdom. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2006-12-05.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Osteoarthritis, Hip with a site in United Kingdom — 5 open to participants now, 11 under way, none of them phase 3. Osteoarthritis, Hip · United Kingdom.
Among the 32 studies in Osteoarthritis, Hip with a site in United Kingdom, this one is the 8th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2003, is one of 2 in phase 4, and was the 3rd registered.
641 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.
Browse Osteoarthritis, Hip studies →5 of the 32 studies in Osteoarthritis, Hip with a site in United Kingdom are open now. Recruiting first, the newest first:
Embody Orthopaedic Limited · Sites in United Kingdom
Middlesex University · Sites in United Kingdom
Ages 18+
Hospital for Special Surgery, New York · Sites in United Kingdom, United States
Ages 18+
Waldemar Link GmbH & Co. KG · Sites in United Kingdom, Germany
Ages 18+
The Royal Orthopaedic Hospital NHS Trust · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 87 Osteoarthritis, Hip studies recruiting now, 54 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 90 across 457 interventional studies indexed under Osteoarthritis, Hip.
Median enrollment 125 across the 23 interventional studies, 200 across the 9 observational. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 32 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 7 studies filed under Osteoarthritis, Hip — fewer than ten, so there is no comparison to draw.
2 of the studies in Osteoarthritis, Hip with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05675618Hospital for Special Surgery, New YorkReturn to Golf After Orthopaedic Surgery | 2026-12 |
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Osteoarthritis, Hip with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine if celecoxib 200 mg once daily is as effective as diclofenac 50 mg three times daily in the treatment of pain symptoms associated with osteoarthritis of the hip
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Change in patient assessment of arthritis pain on walking VAS (Visual Analog Scale) as measured on a 0-100 mm scale at week 6 compared to baseline
Change in patient assessment of arthritis pain on walking VAS (Visual Analog Scale) as measured on a 0-100 mm scale at week 12 compared to baseline.
Change in patients global assessment of arthritis between treatment groups.
The record gives a start of Aug 2003 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Celecoxib · Diclofenac